Skip to main content
HR 7113 116th Congress House Health Blood and blood diseases Cardiovascular and respiratory health Congressional oversight Corporate finance and management Department of Health and Human Services Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Executive agency funding and structure Federal officials Genetics Government ethics and transparency, public corruption Government information and archives Government studies and investigations Health personnel Health technology, devices, supplies Immunology and vaccination Indian social and development programs Infectious and parasitic diseases Inflation and prices

COVID–19 Emergency Manufacturing Act of 2020

Introduced: June 4, 2020 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 4, 2020
Referred to the House Committee on Energy and Commerce.
Jun 4, 2020
Introduced in House
 Plain-English summary Congressional Research Service

COVID-19 Emergency Manufacturing Act of 2020

This bill establishes within the Department of Health and Human Services (HHS) an Emergency Office of Manufacturing for Public Health to manufacture and distribute medical products to address COVID-19 (i.e., coronavirus disease 2019) or medical products that are on shortage or vulnerable to shortage.

The office must (1) obtain the rights to manufacture the applicable medicines, ingredients, diagnostic tests, medical devices, personal protective equipment, and supplies; (2) manufacture or contract to manufacture such items; and (3) construct, or enter into construction contracts for, facilities to manufacture certain medicines, such as vaccines.

HHS may issue involuntary licenses allowing the office to make, use, sell, import, or export an invention related to an applicable drug, biological product, or device and to use clinical trial data and confidential information. Such a license must provide the rights holder with reasonable compensation.

The office must (1) provide such COVID-19 products at no cost to federal, state, local, and other health programs and certain domestic health care providers and suppliers; (2) offer COVID-19 products at cost to other commercial and international entities; and (3) offer other medical products to entities at a fair price, based on cost and other considerations.

The office shall prioritize the manufacture of certain COVID-19 products and meet manufacturing timelines specified in the bill.

What's happening now June 4, 2020

Referred to the House Committee on Energy and Commerce.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1